Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT05219513
- Locations
- 🇫🇷
CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang, Lille, France
🇮🇹ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
🇮🇹Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT05211336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 650
- Registration Number
- NCT05197192
- Locations
- 🇩🇪
Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
🇩🇪DRK Kliniken Berlin Köpenick, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program, San Francisco, California, United States
🇮🇹Irccs Ospedale San Raffaele;U.O. Oculistica, Milano, Lombardia, Italy
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 42
- Registration Number
- NCT05169658
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT05105841
- Locations
- 🇯🇵
National Cancer Center Hospital /ID# 232449, Chuo-ku, Tokyo, Japan
🇯🇵University Hospital Kyoto Prefectural University of Medicine /ID# 239883, Kyoto-shi, Kyoto, Japan
🇯🇵Tohoku University Hospital /ID# 238433, Sendai-shi, Miyagi, Japan
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 750
- Registration Number
- NCT05100862
- Locations
- 🇺🇸
Ucsf Fresno University of California San Francisco Fresno, Fresno, California, United States
🇺🇸Kaiser Permanente Southern California, Irvine, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 607
- Registration Number
- NCT05057494
- Locations
- 🇪🇸
Research Site, Palma de Mallorca, Spain
Obinutuzumab in Primary MN
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-03-06
- Target Recruit Count
- 20
- Registration Number
- NCT05050214
- Locations
- 🇮🇹
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica, BG, Italy
🇮🇹ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05039619
- Locations
- 🇪🇸
Hospital Ramon y Cajal ; Servicio de Reumatologia, Madrid, Spain
🇺🇸University of California San Francisco, San Francisco, California, United States
🇧🇷Universidade Federal de Sao Paulo - UNIFES, Sao Paulo, SP, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.